Pfizer Inc.PFENYSE
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank49
3Y CAGR-35.9%
5Y CAGR-41.2%
Year-over-Year Change
Year-over-year free cash flow growth rate
3Y CAGR
-35.9%/yr
vs -17.8%/yr prior
5Y CAGR
-41.2%/yr
Recent acceleration
Acceleration
-18.1pp
Decelerating
Percentile
P49
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 12.57% |
| Q3 2025 | 433.42% |
| Q2 2025 | -167.76% |
| Q1 2025 | -69.49% |
| Q4 2024 | -4.27% |
| Q3 2024 | 350.74% |
| Q2 2024 | -726.42% |
| Q1 2024 | -90.80% |
| Q4 2023 | 58.58% |
| Q4 2023 | 224.63% |
| Q3 2023 | -2968.92% |
| Q2 2023 | -99.02% |
| Q4 2022 | 47.69% |
| Q4 2022 | -30.80% |
| Q3 2022 | 25.77% |
| Q2 2022 | 19.85% |
| Q4 2021 | -51.78% |
| Q4 2021 | -5.15% |
| Q3 2021 | 170.06% |
| Q2 2021 | -8.18% |
| Q4 2020 | 178.14% |
| Q3 2020 | -49.27% |
| Q2 2020 | 16.57% |
| Q1 2020 | -13.31% |
| Q4 2019 | -20.92% |
| Q3 2019 | 90.21% |
| Q2 2019 | 87.31% |
| Q1 2019 | -72.63% |
| Q4 2018 | -15.99% |
| Q3 2018 | 38.51% |
| Q3 2018 | 112.34% |
| Q2 2018 | -73.25% |
| Q4 2017 | 39.14% |
| Q4 2017 | 55.27% |
| Q3 2017 | 124.45% |
| Q2 2017 | -76.34% |
| Q4 2016 | 21.94% |
| Q4 2016 | 38.45% |
| Q3 2016 | 128.30% |
| Q2 2016 | -66.67% |